Recipient-type specific CD4⁺CD25⁺ regulatory T cells favor immune reconstitution and control graft-versus-host disease while maintaining graft-versus-leukemia
J. Clin. Invest. Aurélie Trenado, et al. 112:1688 doi:10.1172/JCI17702 [Go to this article.]

Figure 4
Comparison of in vitro and in vivo properties of cultured sTreg’s and irTreg’s. (a and b) 1 × 10⁶ sTreg’s or irTreg’s were labeled with CFSE and injected into semiallogeneic, nonirradiated [BALB/c × C3H]F1. At days 3, 10, and 28, splenocytes from grafted animals were collected. The injected Treg’s were detected in the spleen of grafted animals by the expression of the Thy-1.1 congenic marker. Cell proliferation was measured as the sequential loss of CFSE within the Thy-1.1⁺ cell population by flow cytometry (a) and by the count of the absolute number of Thy-1.1⁺ cells in the spleen (magnitude ×100) (b). (c) 1 × 10⁶ sTreg’s or irTreg’s were labeled with CFSE and injected into semiallogeneic irradiated [BALB/c × C3H]F1. At day 3, splenocytes from grafted animals were collected and cell division of donor cells was evaluated. (d) The in vitro suppressive properties of cultured Treg’s were tested after 3 weeks of culture. BALB/c CD25-depleted cells (effector T cells, white bar) were stimulated either by C3H APCs (left panel) or B6 APCs (right panel). Cells were cocultured with BALB/c sTreg’s (black bar) or irTreg’s (gray bar) in order to assess their suppressive activity. This figure is representative of three independent experiments.